A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

Abstract Background Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC). HCRN GI15-225 is an open-label, single-arm multicenter, pilot study (NCT03099564). Methods Eligib...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Jg. 29; H. 3; S. 270 - e413
Hauptverfasser: Yu, Shawn, Yu, Menggang, Keane, Barry, Mauro, David M, Helft, Paul R, Harris, William P, Sanoff, Hanna K, Johnson, Matthew S, O’Neil, Bert, McRee, Autumn Jackson, Somasundaram, Ashwin
Format: Journal Article
Sprache:Englisch
Veröffentlicht: US Oxford University Press 01.03.2024
Schlagworte:
Care and treatment
Clinical Trial Results
Combined modality therapy
Hepatoma
Liver cancer
Medical prognosis
Methods
Pilot projects
Radiotherapy
United States
pembrolizumab
glass Y90 radioembolization
hepatocellular carcinoma
immunotherapy
TARE
ISSN:1083-7159, 1549-490X, 1549-490X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC). HCRN GI15-225 is an open-label, single-arm multicenter, pilot study (NCT03099564). Methods Eligible patients had poor prognosis, localized HCC defined as having portal vein thrombus, multifocal disease, and/or diffuse disease that were not eligible for liver transplant or surgical resection. Patients received pembrolizumab 200 mg intravenously every 3 weeks in conjunction with glass yttrium-90 (Y90) radioembolization TheraSphere. Primary endpoint was 6-month progression-free survival (PFS6) per RECIST 1.1. Secondary endpoints included time to progression (TTP), objective response rate (ORR), overall survival (OS), and safety/tolerability. Results Between October 23, 2017 and November 24, 2020, 29 patients were enrolled: 2 were excluded per protocol. Fifteen of the remaining 27 patients were free of progression at 6 months (55.6%; 95% CI, 35.3-74.5) with median PFS 9.95 months (95% CI, 4.14-15.24) and OS 27.30 months (95% CI, 10.15-39.52). One patient was not evaluable for response due to death; among the remaining 26 patients, ORR was 30.8% (95% CI, 14.3-51.8) and DCR was 84.6% (95% CI, 65.1-95.6). Conclusion In patients with localized, poor prognosis HCC, pembrolizumab in addition to glass Y90 radioembolization demonstrated promising efficacy and safety consistent with prior observations (ClinicalTrials.gov Identifier: NCT03099564; IRB Approved: 16-3255 approved July 12, 2016). This pilot study explored whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic hepatocellular carcinoma is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
Shawn Yu and Menggang Yu Co-first authors.
Principal Investigator: Ashwin Somasundaram
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1093/oncolo/oyad331